NEW YORK, -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with two times higher activity of the Company's investigational new drug Actimab-A.
"This is a significant milestone for our company," commented Jack Talley, CEO of Actinium Pharmaceuticals. "Our program is now advancing rapidly, offering new hope for patients who were until now generally considered untreatable, as additional leading cancer treatment centers continue to join our trial."
The trial is a prospective, open-label study, designed to determine the safety and efficacy of Actimab-A in newly diagnosed AML patients who cannot tolerate current high dose chemotherapeutic regimens.
Mr. Talley added, "Acute myeloid leukemia in patients over the age of 60 is a serious unmet need and we are eager to make this treatment available to patients."
Actimab-A is being developed using Company's proprietary patented APIT technology and it consists of the monoclonal antibody Lintuzumab used to guide the alpha emitting radioisotope actinium 225 to malignant cells.
PR Newswire